<DOC>
	<DOCNO>NCT00016367</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining chemotherapy monoclonal antibody therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine cisplatin , gemcitabine , trastuzumab treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Cisplatin Gemcitabine Plus Trastuzumab Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine therapeutic efficacy toxicity cisplatin , gemcitabine , trastuzumab ( Herceptin ) patient untreated p185-HER2 overexpressing stage IIIB IV non-small cell lung cancer . II . Determine pharmacokinetic interaction among drug patient . III . Assess pharmacodynamics drug patient . OUTLINE : This multicenter study . Regimen A : Patients receive gemcitabine IV 30 minute follow cisplatin IV 2 hour day 1 trastuzumab ( Herceptin ) IV 90 minute day 2 . Patients receive trastuzumab IV 90 minute follow gemcitabine IV 30 minute day 8 trastuzumab IV 90 minute day 15 . Patients proceed regimen B day 22 regimen A . Regimen B : Patients receive trastuzumab IV 30-90 minute , gemcitabine IV 30 minute , cisplatin IV 2 hour day 1 . Patients receive trastuzumab IV 30-90 minute follow gemcitabine IV 30 minute day 8 trastuzumab IV 30-90 minute day 15 . Treatment repeat every 21 day 5 course absence disease progression unacceptable toxicity . Maintenance : After completion 6 course , patient stable disease partial response receive trastuzumab IV 30-90 minute weekly tumor progression . PROJECTED ACCRUAL : A total 20-48 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Immunohistochemically confirm p185HER2 express stage IIIB ( pleural effusion ) IV nonsmall cell lung cancer Confirmed overexpression least : 1+ p185HER2 ( DAKO Hercep Test ) OR 15 ng/mL serum HER2/neu shed antigen ( Human HER2 Quantitative ELISA ) At least 1 site measurable disease outside prior radiation port Brain metastases allow provided clinical neurologic status stable head CT scan stable improve PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Zubrod 02 Life expectancy : More 12 week Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL ( transfusion allow ) Hepatic : Bilirubin le 1.5 mg/dL SGPT great 1.5 time normal Renal : Creatinine clearance least 60 mL/min Cardiovascular : No myocardial infarction within past 6 month No unstable angina , uncontrolled congestive heart failure , uncontrolled arrhythmia Ejection fraction least 40 % Other : No malignancy within past 5 year No concurrent serious infection , include postobstructive pneumonia No 10 % weight loss past 3 month Not pregnant nursing Negative pregnancy test Fertile patient must use adequate contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy ( include radiotherapy brain metastasis ) No concurrent radiotherapy site measurable disease Surgery : At least 2 week since prior major surgery No concurrent surgery site measurable disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>